Hindustan Foods Ltd Q3 FY2024 Concall Summary

Key Takeaways

• Record quarterly turnover despite seasonal headwinds: Ice cream and beverage seasonality plus integration costs from two new acquisitions weighed on the quarter, yet the company still delivered its highest-ever quarterly revenue.
• Integration drag persists for one more quarter: The Baddi OTC pharma unit and KNS Shoetech sports shoe acquisitions will continue to pressure financials through Q4 FY24 before normalizing in Q1 FY25.
• The pass-through model cuts both ways: Gross margin improvement came entirely from commodity deflation, not operational gains; management was explicit that the same mechanism hurt margins when inflation spiked 1.5 years ago.
• Shared manufacturing is the high-stakes bet: The sports shoe business carries no take-or-pay contracts, meaning operating leverage can drive outsized ROE or produce losses if customers walk away, a risk the company is consciously taking after raising growth capital.
• What to watch next quarter: Whether Baddi and KNS Shoetech integrations actually normalize, the pace of ramp-up at the new Guwahati juice line, and any concrete revenue visibility on the remaining ₹600 crores of the planned ₹900 crores gross block addition.

Integration Overhang

• Baddi unit closed after long delay: The transaction, held up for statutory permissions for more than three quarters, finally closed; the factory is a regulated OTC pharma site with US FDA, MHRA and Russian FDA approvals, carrying a completely different risk profile than the company's FMCG manufacturing.
• The cost of integration: In the previous quarter, Baddi had 15 days of accrued period with no revenue, resulting in a hit of approximately ₹3 crores plus salaries; this drag continues in the current quarter because the company is still working on license transfers.
• KNS Shoetech layered on more complexity: The initial acquisition carried a ~₹1 crore hit last quarter; since then, the company announced one more facility acquisition (manufacturing assets of KNS Trading) and secured Board authorization for a third sports shoe facility, extending the integration timeline.
• ERP and vendor onboarding underway: Nearly 5,000 new raw materials and packaging materials are being onboarded due to the new operations, adding to the near-term operational load.
• Normalization timeline: Management expects both acquisitions to start normalizing in Q1 FY25, with Baddi's anchor tenant (Reckitt Benckiser, on a take-or-pay contract) normalizing within 3 to 6 months and full capacity ramp-up taking about a year.

Sameer Kothari: "Frankly, the team, including me have done nothing to improve that margin. It has just happened by the fact that there's been deflation in commodities. The flip side is also true. If you look at our performance 1.5 years ago, when inflation was at its peak, our margins were deteriorating. And again, our team was not to be blamed for it. That's just the way the model works."

The Sports Shoe Pivot

• A structural market shift: The global sports shoe and sneaker manufacturing base is moving from China to Vietnam, Bangladesh, and now beginning to come to India; substantial money is being invested in the sector, and the company sees an opportunity to apply its contract manufacturing playbook.
• Shared manufacturing, no safety net: Unlike the company's core FMCG model where 80-85% of the asset block sits on take-or-pay contracts, the entire shoe business operates on shared manufacturing with no guaranteed offtake; customers can walk in or out at any point, and the company carries the full volume risk.
• The ROE math: The shoe business is predominantly labor-intensive with lower total investment compared to capital-heavy facilities like ice cream, so ROE potential is higher; but the absence of take-or-pay contracts means operating leverage works in both directions.
• Learning from a stagnant legacy: The company has had a leather shoe business since 2016 (acquired from Hindustan Unilever's Erstwhile Pond Export) but has not been able to grow it because the leather shoe market stagnated across Europe and the US through COVID and post-COVID cycles.
• Domestic distribution angle: For the domestic market, the company is offering a distributor manufacturing strategy, setting up facilities close to customers: a Bata facility in West Mumbai and another in Tindivanam, Chennai.
• Integration and guidance timeline: The shoe business will take about a quarter to integrate; management expects it to become sizable within six months, after which it will provide definite guidance on gross margins.

Sameer Kothari: "The shoe business here is going to be the trump or the joker depending on what you say because if we are able to successfully integrate the business and ramp it up, the ROE expectation for the shoe business is much higher."

Revenue Engine & the ₹4,000 Crore Target

• Target firmly reiterated: Management expressed confidence in reaching ₹4,000 crores turnover by FY25, a target discussed for over a year, and stated the company is "well on track."
• The investment pipeline: The company plans to invest approximately ₹800-900 crores in gross block over the next two years, targeting a gross block of ~₹1,800 crores by FY26, funded through the ₹400 crore preferential issue (warrant structure, 25% received upfront), debt, and internal accruals.
• Where the money is going: ₹128 crores already invested in Baddi; ₹35 crores invested in shoes with another ₹100 crores committed; ~₹25 crores in the Guwahati juice line for Dabur; ₹100 crores in the new Haryana ice cream facility.
• Revenue visibility gap: When asked what the ₹375-400 crores of total investment would translate to in revenue, management declined to provide a breakdown, pointing only to the ₹4,000 crores top-line target; the remaining ₹600 crores of the planned gross block addition also lacks specific project visibility and sits in the pipeline.
• FMCG wallet share runway: At least 3-4 large FMCG companies with COGS budgets exceeding ₹5,000-10,000 crores each are not yet clients, representing zero wallet share; however, the current FMCG environment is "a little tough" with no volume growth, and projects remain stuck in the pipeline because customers see no need for extra capacity.
• The counter-cyclical argument: In a no-volume-growth environment, management believes FMCG companies may look more toward contract manufacturing to improve their own margins, potentially accelerating outsourcing.

Sameer Kothari: "I can rattle off at least 3 or 4 names of large FMCG companies in the country who are currently not our clients. And as a result, we have 0 wallet share from them."

Business Model Mechanics

• Pass-through dominates the P&L: Before the shoe business, 80-85% of the business operates on a pass-through model for raw material and packing material costs; gross margin movements are almost entirely a function of commodity cycles, not management action.
• Dedicated vs shared manufacturing: In dedicated manufacturing with take-or-pay contracts, there is no operating leverage: even if revenues or capacity utilization increase, it makes no difference to the bottom line. Shared manufacturing, by contrast, has uncapped IRR potential but also uncapped downside.
• The COVID precedent: The company's Mysuru beverage unit, operating on shared manufacturing, made losses during COVID when all customers walked away, a risk that now applies to the shoe business.
• Risk profile shift underway: With an asset block of ₹1,000 crores (80-85% on take-or-pay), the company has confirmed revenue and cash flow visibility; the recent equity raise is explicitly growth capital to take on higher-risk, higher-return opportunities, including tying up with new-age brands for dedicated ice cream manufacturing rather than only working with large MNCs.
• Baddi as a margin lever: The OTC pharma unit should deliver better ROE than the core FMCG business because it is a regulated site with a different risk profile; management benchmarks ROEs against the risk taken.

Sameer Kothari: "In case of dedicated manufacturing where we have a take-or-pay contract, we do not have any operating leverage. So even when revenues go up or the capacity utilization becomes better in those factories, it actually will not make any difference to our bottom line."

Project Pipeline & Ramp-Up Timelines

• Guwahati juice line imminent: The Dabur job-work facility (~₹25 crores investment) starts commercial production in the third week of the month; since Dabur supplies raw and packing materials and HFL earns only conversion costs, the top-line impact is limited.
• Haryana ice cream plant: A greenfield facility with ₹100 crores CapEx, signed on land from Central Warehousing Corporation in Kundli; partial production expected by Q3 FY25, with full ramp-up by Q4 FY25 to capture the summer season.
• Beverage seasonality bet: The Guwahati juice line and the existing Mysuru beverage facility are both positioned for Q4 FY24 seasonal demand; management noted the outcome depends on "weather gods."
• Baddi full ramp-up: Anchor tenant normalization in 3-6 months; full capacity ramp-up over approximately one year, with contractual flexibility giving years to develop new customers for the balance capacity.
• M&A vs greenfield: The company pursues two types of opportunities: greenfield projects from customers redrawing manufacturing footprints (long-term, geographically specific) and consolidation of stressed or distressed assets from existing contract manufacturers unable to scale; M&A brings revenue from day one of closing, unlike greenfield projects.

Guidance & Commitments

Key Metrics